Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 26, 2007

OncoMethylome Sciences Inks Biomarker Development Deal with GSK

  • OncoMethylome Sciences and GlaxoSmithKline Biologicals will collaborate to develop DNA methylation biomarkers for use in the personalization of cancer treatment with certain immunotherapeutics in development by GSK Biologicals.

    "We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals," commented Jim DiGuiseppi, CTO of OncoMethylome. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »